Annual registry reports

Personalise
Magnifying glass and documents with analytics data lying on table,selective focus

ANZARD annual reports

Summary
  • There were 108,913 ART treatment and lab-only cycles performed in Australian and New Zealand ART Units
  • More than one in three (34.6%) oocyte/embryo recipient cycles were in single females or female-female couples
  • The average age of female patients undergoing autologous and recipient cycles was 36 years
  • Male factor infertility was reported in approximately one in three cycles, where the principal cause of male infertility was unexplained in the majority (76.6%) of these cycles
  • Thaw cycles (31.8%) had higher live birth rates than fresh cycles (14.7%)
  • There were 20,058 babies born following ART treatment in Australia and New Zealand
  • More than one third (38.9%) of women achieved a live birth in their first complete ART cycle
Summary

* Over 110,000 ART treatment cycles were performed in Australia and New Zealand in 2021

* One in three recipient cycles were in single females or female-female couples

* The average age of female patients undertaking ART in 2021 was 36 years

* One in three cycles attributed to male infertility 

* Thaw cycles had higher live birth rates than fresh cycles

* More than 20,000 babies were born following ART treatment in Australia and New Zealand

* More than one third of women achieved a live birth in their first ever complete ART cycle

* Live birth rates per thaw cycle continue to increase

Summary

There were 111,253 ART treatment cycles performed in Australian and New Zealand ART Units in 2021 (102,157 and 9,096 respectively). This represents an increase of 17.1% in Australia and 7.1% in New Zealand from 2020. This equates to 19.6 cycles per 1,000 women of reproductive age (15–44 years) in Australia, compared with 8.7 cycles per 1,000 women of reproductive age in New Zealand. Communities and health services were affected by the COVID pandemic in 2020 and 2021.

Summary

There were 88,929 ART treatment cycles reported from Australian and New Zealand fertility clinics in 2019 (81,049 and 7,880 respectively), representing an increase of 6.2% in Australia and 2% in New Zealand from 2018. This equates to 15.6 cycles per 1,000 women of reproductive age (15–44 years) in Australia, compared with 7.9 cycles per 1,000 women of reproductive age in New Zealand. Women used their own oocytes or embryos (autologous cycles) in 95% of treatments. Embryos and oocytes that had been frozen and thawed were used in 36.7% of autologous cycles.

There were 84,064 ART treatment cycles reported from Australian and New Zealand fertility clinics in 2018 (76,341 and 7,723 respectively), representing an increase of 1.9% in Australia and 6.2% in New Zealand from 2017. This equates to 14.8 cycles per 1,000 women of reproductive age (15–44 years) in Australia, compared with 7.9 cycles per 1,000 women of reproductive age in New Zealand. Women used their own oocytes or embryos (autologous cycles) in 94.1% of treatments. Embryos and oocytes that had been frozen and thawed were used in 36.9% of autologous cycles.

There were 82,215 ART treatment cycles reported from Australian and New Zealand fertility clinics in 2017 (74,942 and 7,273 respectively), representing an increase of 0.8% in Australia and 8.5% in New Zealand from 2016. This equates to 14.8 cycles per 1,000 women of reproductive age (15–44 years) in Australia, compared with 7.6 cycles per 1,000 women of reproductive age in New Zealand. Women used their own oocytes or embryos (autologous cycles) in 94.1% of treatments. Embryos and oocytes that had been frozen and thawed were used in 38.5% of autologous cycles.

ANZNN annual reports

ICMART reports